Sonnet BioTherapeutics Reports Key Developments and Trials

Introduction

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) is a clinical-stage biotechnology company based in Princeton, New Jersey. At market close on July 7, 2025, shares traded on the Nasdaq Capital Market at $5.97, up 52.30 percent for the day, on a volume of 6,988,042 shares. Sonnet specializes in immuno-oncology therapies, leveraging its proprietary FHAB™ (Fully Human Albumin-Binding) platform to deliver targeted biologic drugs.

Corporate Structure

Founded in 2011, Sonnet employs between 11 and 50 people, including scientists, clinicians, and business professionals. The company is led by Founder and Chief Executive Officer Pankaj Mohan, Ph.D., with Susan Dexter serving as Chief Technology Officer. Sonnet’s team collaborates across research, development, and regulatory functions to advance five cytokine-derived candidates through preclinical and clinical stages.

Biotechnology by National Cancer Institute

Recent Developments and News

On July 2, 2025, Sonnet filed a Form 8-K reporting material agreements, financing obligations, equity issuances, and related exhibits (Items 1.01, 2.03, 3.02, and 9.01). Earlier, on June 2, 2025, the company filed another Form 8-K disclosing changes in executive officers and other material events (Items 3.01 and 8.01).

In its May 13, 2025 quarterly report (Form 10-Q), Sonnet provided updates on its financial position, including research and development expenses, general and administrative costs, net loss for the period, and cash and cash equivalents. While net revenues remain limited, the company highlighted its cash runway and R&D investments.

Beyond regulatory filings, Sonnet announced on October 16, 2024, that it had regained compliance with Nasdaq’s minimum bid price rule. Under a one-year monitoring period ending October 16, 2025, the company must maintain a share price above the required threshold to avoid delisting procedures.

On December 23, 2024, Sonnet released the latest “CEO Corner” video segment, in which Dr. Mohan summarized the company's achievements in 2024 and outlined milestones targeted for 2025 across Sonnet’s pipeline and strategic partnerships.

Financial and Strategic Analysis

Sonnet’s strategic partnerships underpin its clinical programs. Through a Material Supply Agreement with Roche, SON-1010 (IL-12-FHAB) is being evaluated in a Phase 1/2a trial in combination with atezolizumab for platinum-resistant ovarian cancer. Its second lead, SON-1210 (IL-12-FHAB-IL-15), is under investigation in an investigator-initiated Phase 1/2a study for pancreatic cancer at the Sarcoma Oncology Center. The SON-080 program, a low-dose rhIL-6 candidate for chemotherapy-induced and diabetic peripheral neuropathies, demonstrated tolerability in a Phase 1b/2a trial and is now positioned for partnership discussions to support a Phase 2 trial.

In October 2019, Sonnet completed a merger with Chanticleer Holdings, including a $19 million private placement and the acquisition of global development rights to Atexakin Alfa from Relief Therapeutics. The transaction involved the spinoff of the restaurant business of the public entity, leaving Sonnet focused on biologic drug development.

Sonnet’s Form 10-Q reflects ongoing R&D spending as the primary operating expense, which is consistent with peer clinical-stage biotechs. While revenues remain minimal, the company maintains sufficient cash balances to fund ongoing trials and operations, subject to disciplined expense management and potential milestone payments from collaborations.

Market Position and Industry Context

Sonnet operates in the competitive immuno-oncology sector, where converting immunologically “cold” tumors to “hot” is a key therapeutic goal. Its FHAB platform differentiates the company by extending half-life and enhancing tissue targeting of cytokine-based biologics. With a pipeline of five therapeutic candidates, Sonnet addresses unmet needs in solid tumors and neuropathies. The company’s small size provides operational flexibility, but it must navigate regulatory reviews, clinical trial risks, and capital-raising requirements typical of early-stage biotech firms.

tl;dr

On July 2, 2025, Sonnet filed an 8-K disclosing new agreements, financing obligations, and executive changes, following a June 2, 2025, 8-K on officer appointments. Its May 13, 2025, 10-Q detailed R&D spending, net loss, and cash reserves. SON-1010 is in Phase 1/2a with Roche for ovarian cancer, SON-1210 is in Phase 1/2a for pancreatic cancer, and SON-080 is preparing for Phase 2 partnerships. Since regaining Nasdaq bid-price compliance on October 16, 2024, the company remains under monitoring until October 16, 2025. Future milestones include Phase 2 trial initiations and potential collaboration deals.